Cover Image

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014-2015 Northern Hemis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhaojun Mo (Author), Yi Nong (Author), Shuzhen Liu (Author), Ming Shao (Author), Xueyan Liao (Author), Kerry Go (Author), Nathalie Lavis (Author)
Format:	Book
Published:	Taylor & Francis Group, 2017-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
by: Yuemei Hu, et al.
Published: (2019)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011)

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
by: Sandrine I. Samson, et al.
Published: (2019)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
by: Xiaoqiang Liu, et al.
Published: (2022)

Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults
by: Ahmed Tawfik, et al.
Published: (2023)

Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine
by: Marc Demeulemeester, et al.
Published: (2017)

Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
by: Yan Li, et al.
Published: (2021)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
by: Goran Stevanovic, et al.
Published: (2018)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
by: Suvanna Asavapiriyanont, et al.
Published: (2018)

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan
by: Gulbanu Sarsenbayeva, et al.
Published: (2020)

Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults
by: Joon Young Song, et al.
Published: (2019)

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
by: Shi-Yuan Wang, et al.
Published: (2017)

Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants
by: Shelina Moonsamy, et al.
Published: (2019)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
by: Timo Vesikari, et al.
Published: (2020)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
by: Goran Stevanovic, et al.
Published: (2020)

Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore
by: Yuk-Fai Lau, et al.
Published: (2017)

Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
by: Kei Nakashima, et al.
Published: (2017)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
by: Pablo Manuel Bianculli, et al.
Published: (2022)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
by: Francesco Saverio Mennini, et al.
Published: (2018)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
by: Cecilia Montalban, et al.
Published: (2018)

Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis
by: Yu Liang, et al.
Published: (2021)

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
by: Phan Trong Lan, et al.
Published: (2019)

Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial
by: Wayne M Sullender, ProfMD, et al.
Published: (2019)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
by: Antonio Arbo, et al.
Published: (2022)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
by: Guillermo M. Ruiz-Palacios, et al.
Published: (2020)

IMMUNOGENICITY AND SAFETY OF A TRIVALENT SUBUNIT IMMUNOADJUVANT INFLUENZA VACCINE IN CHILDREN WITH TYPE 1 DIABETES: RESULTS OF A PROSPECTIVE COMPARATIVE STUDY
by: Аlla A. Tarasova, et al.
Published: (2016)

Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine
by: Huakun Lv, et al.
Published: (2021)

Immunogenicity and safety of inactivated Influenza Split-Virion vaccine administered via a Transdermal Microneedle System
by: Mahmoud Ameri, et al.
Published: (2021)

Immunogenicity of a trivalent influenza vaccine and persistence of induced immunity in adults aged ≥60 years in Taizhou City, Zhejiang Province, China, during the 2018-2019 season
by: Yuting Liao, et al.
Published: (2022)

Effect of aging on immunogenicity and efficacy of inactivated influenza vaccines in cotton rats Sigmodon hispidus
by: Marina S. Boukhvalova, et al.
Published: (2021)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
by: Sharad Agarkhedkar, et al.
Published: (2019)

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China
by: Yuemei Hu, et al.
Published: (2020)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
by: Ainur Nurpeisova, et al.
Published: (2022)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines
by: Allegra Peletta, et al.
Published: (2024)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India
by: Nijalingappa K. Kalappanavar, et al.
Published: (2022)

Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
by: Xia Wei, et al.
Published: (2023)

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
by: Margaret Haugh, et al.
Published: (2017)

Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.
by: Shi-Hsia Hwa, et al.
Published: (2013)